Cyclic nucleotide phosphodiesterases (PDEs), by catalyzing the breakdown reaction, play essential roles in the regulation of the magnitude, duration, and compartmentation of individual cyclic nucleotide pools. However, little is known about the causal relationship between alterations of PDE expression/activity and cardiac dysfunctions. The objective of this project is to understand the regulation and function of PDE3A isoform in cardiac gene expression and the progression of heart failure. PDE3A is one of the important cAMP-hydrolyzing PDEs in cardiac myocytes. Recently, we found that the expression of PDE3A is downregulated in human and animal failing hearts. Downregulation of PDE3A is associated with myocyte apoptosis through sustained induction of a transcriptional repressor ICER (inducible cAMP early repressor) and thereby inhibition of anti- apoptotic molecule Bcl-2 expression, which provides the molecular mechanism for how chronic angiotensin II (Ang II) and 2-adrenergic receptor (2-AR) stimulation induce myocyte apoptosis. Interestingly, the sustained ICER induction is maintained by a positive feedback mechanism involving the interactions between PDE3A and ICER (referred to PDE3A-ICER feedback loop). Specifically, ICER represses PDE3A gene transcription and PDE3A reduction stimulates cAMP/PKA signaling, leading to ICER upregulation via PKA-dependent stabilization of ICER protein. In addition to the pro-apoptotic effect, our preliminary data show that sustained ICER induction may downregulate a number of other proteins that critically regulate myocyte contractile function and electrophysiology. PDE3A is a key regulator of the positive feedback loop since we demonstrated that preserving PDE3A function terminates the feedback loop and prevents the sustained ICER induction. Therefore, we hypothesize that the PDE3A-ICER feedback loop is a pathogenic mediator of cardiac dysfunction and heart failure, and maintaining PDE3A expression and function will be an attractive approach to block the PDE3A-ICER feedback loop and prevent the progression of heart failure. To test the hypothesis, we propose three aims, Aim 1: Determine the roles and mechanisms of the PDE3A-ICER feedback loop in cardiac myocyte dysfunction;
Aim 2 : Define the molecular mechanisms that stimulate PDE3A gene expression and thereby prevent the PDE3A-ICER positive feedback loop;
Aim 3 : Determine if restoring PDE3A function improves cardiac function in animal models of heart failure. Significance: The findings will provide novel insights into the molecular mechanisms underlying the development of heart failure, and may lead to the identification of novel therapeutic targets for treating heart failure.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL088400-03
Application #
7748917
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Liang, Isabella Y
Project Start
2008-01-15
Project End
2011-12-31
Budget Start
2010-01-01
Budget End
2010-12-31
Support Year
3
Fiscal Year
2010
Total Cost
$385,000
Indirect Cost
Name
University of Rochester
Department
Internal Medicine/Medicine
Type
Schools of Dentistry
DUNS #
041294109
City
Rochester
State
NY
Country
United States
Zip Code
14627
Wu, Mei-ping; Zhang, Yi-shuai; Zhou, Qian-mei et al. (2016) Higenamine protects ischemia/reperfusion induced cardiac injury and myocyte apoptosis through activation of β2-AR/PI3K/AKT signaling pathway. Pharmacol Res 104:115-23
Knight, Walter E; Chen, Si; Zhang, Yishuai et al. (2016) PDE1C deficiency antagonizes pathological cardiac remodeling and dysfunction. Proc Natl Acad Sci U S A :
Susuki-Miyata, Seiko; Miyata, Masanori; Lee, Byung-Cheol et al. (2015) Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi. Proc Natl Acad Sci U S A 112:E1800-9
Cai, Yujun; Nagel, David J; Zhou, Qian et al. (2015) Role of cAMP-phosphodiesterase 1C signaling in regulating growth factor receptor stability, vascular smooth muscle cell growth, migration, and neointimal hyperplasia. Circ Res 116:1120-32
Yan, Chen (2015) Cyclic nucleotide phosphodiesterase 1 and vascular aging. Clin Sci (Lond) 129:1077-81
Lee, Ji-Yun; Komatsu, Kensei; Lee, Byung-Cheol et al. (2015) Vinpocetine inhibits Streptococcus pneumoniae-induced upregulation of mucin MUC5AC expression via induction of MKP-1 phosphatase in the pathogenesis of otitis media. J Immunol 194:5990-8
Oikawa, Masayoshi; Wu, Meiping; Lim, Soyeon et al. (2013) Cyclic nucleotide phosphodiesterase 3A1 protects the heart against ischemia-reperfusion injury. J Mol Cell Cardiol 64:11-9
Cai, Yujun; Li, Jian-Dong; Yan, Chen (2013) Vinpocetine attenuates lipid accumulation and atherosclerosis formation. Biochem Biophys Res Commun 434:439-43
Knight, Walter; Yan, Chen (2013) Therapeutic potential of PDE modulation in treating heart disease. Future Med Chem 5:1607-20
Knight, W E; Yan, C (2012) Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects. Horm Metab Res 44:766-75

Showing the most recent 10 out of 29 publications